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ABSTRACT
Objective To examine the performance of screening
for preterm and term pre-eclampsia (PE) in the study
population participating in the ASPRE (Combined Mul-
timarker Screening and Randomized Patient Treatment
with Aspirin for Evidence-Based Preeclampsia Preven-
tion) trial.
Methods This was a prospective first-trimester multi-
center study on screening for preterm PE in 26 941
singleton pregnancies by means of an algorithm that com-
bines maternal factors, mean arterial pressure, uterine
artery pulsatility index and maternal serum pregnancy-
associated plasma protein-A and placental growth factor
at 11–13 weeks’ gestation. Eligible women with an esti-
mated risk for preterm PE of > 1 in 100 were invited to
participate in a double-blind trial of aspirin (150 mg per
day) vs placebo from 11–14 until 36 weeks’ gestation,
which showed that, in the aspirin group, the incidence
of preterm PE was reduced by 62%. In the screened
population, the detection rates (DRs) and false-positive
rates (FPRs) for delivery with PE<37 and ≥ 37 weeks
were estimated after adjustment for the effect of aspirin in
those receiving this treatment. We excluded 1144 (4.2%)
pregnancies because of loss to follow-up or study with-
drawal (n = 716), miscarriage (n = 243) or termination
(n = 185).
Results The study population of 25 797 pregnancies
included 180 (0.7%) cases of preterm PE, 450 (1.7%)
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of term PE and 25 167 (97.6%) without PE. In combined
first-trimester screening for preterm PE with a risk cut-off
of 1 in 100, the DR was 76.7% (138/180) for preterm PE
and 43.1% (194/450) for term PE, at screen-positive rate
of 10.5% (2707/25 797) and FPR of 9.2% (2375/25 797).
Conclusion The performance of screening in the ASPRE
study was comparable with that of a study of
approximately 60 000 singleton pregnancies used for
development of the algorithm; in that study, combined
screening detected 76.6% of cases of preterm PE and
38.3% of term PE at a FPR of 10%. Copyright © 2017
ISUOG. Published by John Wiley & Sons Ltd.
INTRODUCTION
The ASPRE (Combined Multimarker Screening and
Randomized Patient Treatment with Aspirin for
Evidence-Based Preeclampsia Prevention) trial was a
prospective first-trimester multicenter study on screen-
ing for preterm PE in 26 941 singleton pregnancies by
means of an algorithm that combines maternal factors,
mean arterial pressure (MAP), uterine artery pulsatility
index (UtA-PI), and maternal serum pregnancy-associated
plasma protein-A (PAPP-A) and placental growth factor
(PlGF) at 11–13 weeks’ gestation1. The algorithm was
developed from a study of approximately 60 000 singleton
pregnancies; in that study, combined screening detected
76.6% of cases of preterm PE and 38.3% of term PE at a
false-positive rate (FPR) of 10%2.
Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd. ORIGINAL PAPER
ASPRE trial screening performance 493
In the ASPRE study, eligible women with an estimated
risk for preterm PE of > 1 in 100 were invited to
participate in a double-blind trial of aspirin (150 mg
per day) vs placebo from 11–14 weeks until 36 weeks’
gestation1. In the aspirin group, the incidence of preterm
PE was reduced by 62%.
The objective of this study was to report the accuracy of
the previously reported first-trimester model of screening
for PE2 in the screened population of the ASPRE study.
The hypothesis was that the performance of screening
would be similar to that estimated from the original
model.
METHODS
Study design and participants
This was a prospective, multicenter study of singleton
pregnancies at 11 + 0 to 13 + 6 weeks’ gestation in women
attending routine pregnancy care at one of 13 maternity
hospitals in the UK, Spain, Italy, Belgium, Greece and
Israel1. Approval for the trial was obtained from the rel-
evant research ethics committee and competent authority
in each country in which the trial was conducted.
The eligibility criteria were maternal age ≥ 18 years, no
serious mental illness or learning difficulty and singleton
pregnancy with live fetus with no major abnormality
demonstrated on the 11–13-week scan. We excluded
pregnancies with no follow-up and those ending in
termination or miscarriage.
The Standards for Reporting Diagnostic Accuracy
Studies (STARD)3 were adhered to.
Test methods
The index test, or the test for which accuracy has
been evaluated, was the previously reported algorithm
for first-trimester assessment of risk for PE by maternal
factors, MAP, UtA-PI, PAPP-A and PlGF2. Maternal fac-
tors were recorded4, MAP was measured by validated
automated devices and standardized protocol5, transab-
dominal color Doppler ultrasound was used to measure
the left and right UtA-PI and the average value was
recorded6, serum PAPP-A and PlGF concentrations were
measured by an automated device (PAPP-A and PlGF
1-2-3™ kits, DELFIA® Xpress random access platform;
PerkinElmer Inc. Wallac Oy, Turku, Finland). All oper-
ators undertaking the Doppler studies had received the
appropriate Certificate of Competence from The Fetal
Medicine Foundation. Measured values of MAP, UtA-PI,
PAPP-A and PlGF were expressed as a MoM, adjusting
for those characteristics found to provide a substantive
contribution to the log10 transformed value including the
maternal factors in the prior model7–10.
The index test was carried out prospectively in con-
secutive singleton pregnancies at 11 + 0 to 13 + 6 weeks’
gestation; gestational age was determined from measure-
ment of fetal crown–rump length11.
The target condition was PE, as defined by the
International Society for the Study of Hypertension
in Pregnancy12. PE was defined as systolic blood
pressure ≥ 140 mmHg and/or diastolic blood pres-
sure ≥ 90 mmHg on at least two occasions 4 h apart
developing after 20 weeks of gestation in previously
normotensive women. Hypertension was defined as pro-
teinuria ≥ 300 mg in 24 h or two readings of at least
++ on dipstick analysis of midstream or catheter urine
specimens if no 24-h collection was available. PE superim-
posed on chronic hypertension was defined as significant
proteinuria (as defined above) developing after 20 weeks
of gestation in women with known chronic hypertension
(history of hypertension before conception or presence of
hypertension at booking visit before 20 weeks’ gestation
in the absence of trophoblastic disease).
Data on pregnancy outcome were collected from the
hospital maternity records of the women. The obstetric
records of all women with pre-existing or pregnancy-
associated hypertension were examined to determine if
the condition was PE.
Statistical analysis
The previously described algorithm was used for the
calculation of patient-specific risk of delivery with
PE<37 weeks’ gestation2. Eligible women with an
estimated risk for preterm PE of > 1 in 100 were invited
to participate in a double-blind trial of aspirin (150 mg
per day) vs placebo from 11–14 weeks until 36 weeks’
gestation1, which showed that, in the aspirin group, the
incidence of preterm PE was reduced by 62%. In the
screened population, the FPRs and detection rates (DRs)
for delivery with PE<37 and ≥ 37 weeks were estimated
after adjustment for the effect of aspirin in those receiving
this treatment.
RESULTS
Participants
A total of 26 941 women with singleton pregnancy
underwent screening for PE (Figure 1). For the purpose of
this study, we excluded 1144 (4.2%) pregnancies because
of loss to follow-up (n = 716), miscarriage (n = 243)
or termination (n = 185). The group lost to follow-up
included 152 high-risk pregnancies that participated in
the trial but subsequently withdrew consent, of which
78 allowed reporting of their screening data; the baseline
characteristics of the women who withdrew consent were
similar between those assigned to receive aspirin and those
assigned to receive placebo1.
The characteristics of the study population of 25 797
pregnancies are shown in Table 1. In this population, the
risk for preterm PE was > 1 in 100 in 2707 (10.5%)
and ≤ 1 in 100 in 23 090 (89.5%). In the group with a
risk of > 1 in 100, 806 participated in the trial and were
assigned to receive placebo, 785 participated in the trial
and were assigned to receive aspirin and 1116 did not
participate in the trial, either because they did not want
to do so (n = 806) or they did not fulfill the eligibility
criteria (n = 310) due to hypersensitivity to aspirin, peptic
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Risk for preterm PE > 1 in 100
(n = 2707)
Assigned to placebo (n = 806)
• Preterm PE (n = 35)
• Term PE (n = 59)
• No PE (n = 712)
Screened for preterm PE
(n = 26 941)
Excluded (n = 1144)
•  Miscarriage (n = 243)
•  TOP (n = 185)
•  Withdrew consent (n = 152)
•  Lost to follow-up (n = 564)
Study population (n = 25 797)
Assigned to aspirin (n = 785)
• Preterm PE (n = 34*)
• Term PE (n = 53)
• No PE (n = 698)
Did not participate in trial (n = 1116)
• Preterm PE (n = 69)
• Term PE (n = 82)
• No PE (n = 965)
Risk for preterm PE ≤ 1 in 100
(n = 23 090)
• Preterm PE (n = 42)
• Term PE (n = 256)
• No PE (n = 22 792)
Figure 1 Flowchart summarizing screening for preterm pre-eclampsia (PE), interventions and follow-up in 26 941 singleton pregnancies.
*Adjusted number, derived from 13 observed cases and assuming 62% reduction of preterm PE caused by aspirin. TOP, termination of
pregnancy.
Table 1 Characteristics of study population
Characteristic Study population (n = 25 797)
Maternal age (years) 31.7 (27.7–35.2)
Maternal weight (kg) 66.0 (58.7–76.5)
Maternal height (cm) 164 (160–169)
Body mass index (kg/m2) 24.4 (21.8–28.2)
Gestational age (weeks) 12.7 (12.3–13.1)
Racial origin
Caucasian 20 383 (79.0)
Afro-Caribbean 3117 (12.1)
East Asian 517 (2.0)
South Asian 1194 (4.6)
Mixed 586 (2.3)
Medical history
Chronic hypertension 319 (1.2)
Diabetes mellitus 207 (0.8)
APS/SLE 135 (0.5)
Cigarette smoker 2072 (8.0)
Family history of pre-eclampsia 851 (3.3)
Mode of conception
Spontaneous 24 868 (96.4)
In-vitro fertilization 764 (3.0)
Ovulation drugs 165 (0.6)
Parity
Nulliparous 12 181 (47.2)
Parous
No previous pre-eclampsia 13 097 (50.8)
Previous pre-eclampsia 519 (2.0)
No previous SGA 12 767 (49.5)
Previous SGA 849 (3.3)
Interpregnancy interval (years) 2.8 (1.6–4.8)
Data are given as median (interquartile range) or n (%). APS, anti-
phospholipid syndrome; SGA, small-for-gestational-age neonate;
SLE, systemic lupus erythematosus.
ulceration or bleeding disorder, treatment with aspirin
within 28 days before screening or participation in another
drug trial within 28 days before screening.
Test results
The incidence of preterm and term PE in the
screen-positive and screen-negative groups is shown in
Figure 1. In the group assigned to receive aspirin, there
were 13 cases of preterm PE and 53 cases of term PE. The
ASPRE trial demonstrated that administration of aspirin,
compared with placebo, resulted in a 62% reduction in
the incidence of preterm PE but had no significant effect
on the incidence of term PE. Consequently, the observed
number of 13 cases of preterm PE in the aspirin group was
adjusted to the expected number of 34 had these patients
not received aspirin (Figure 1).
The study population of 25 797 pregnancies included
180 (0.7%) cases of preterm PE, 450 (1.7%) of term
PE and 25 167 (97.6%) without PE. In combined
first-trimester screening for preterm PE with a risk cut-off
of 1 in 100, the DR was 76.7% (138/180) for preterm PE
and 43.1% (194/450) for term PE, at a screen-positive rate
of 10.5% (2707/25 797) and FPR of 9.2% (2375/25 797).
DISCUSSION
Main findings
This prospective multicenter study demonstrates the
feasibility of incorporating first-trimester screening for PE
Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 50: 492–495.
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into routine clinical practice. The performance of screen-
ing for PE at 11–13 weeks by a combination of maternal
factors and biomarkers is similar to that estimated from
the original model2. The estimated DR of screening by
maternal factors, MAP, UtA-PI, PAPP-A and PlGF was
77% for PE< 37 weeks and 43% for PE ≥ 37 weeks at a
FPR of 9.2%; the rates in the dataset used for development
of the model were 77%, 38% and 10%, respectively2.
Study limitations
There were two components to the ASPRE study; first,
routine screening of all pregnancies meeting the eligibility
criteria and second, participation of a high proportion
of the screen-positive group in a trial of aspirin vs
placebo1. The trial demonstrated a beneficial effect of
aspirin in reducing the rate of preterm PE and therefore
the observed number of cases with preterm PE in the
aspirin group had to be adjusted to take into account
this beneficial effect. In this respect, this was not a
non-intervention validation study.
Implications for practice
The ASPRE trial demonstrated that, in women with
singleton pregnancy who were identified by means of
first-trimester combined screening as being at high risk
for preterm PE, the administration of aspirin at a dose
of 150 mg per day from 11–14 weeks until 36 weeks’
gestation reduces the incidence of preterm PE by > 60%1.
The traditional approach of identifying women at
high risk of PE who could potentially benefit from
the prophylactic use of aspirin is based on maternal
characteristics and medical history. In the UK, the
National Institute for Health and Care Excellence (NICE)
recommends the identification of the high-risk group on
the basis of 10 factors, including maternal characteristics
and features of the medical and obstetric histories13.
However, the performance of such screening is poor,
with a DR of preterm PE of 39% at a FPR of 10%14.
In the USA, the American College of Obstetricians and
Gynecologists (ACOG) recommends the use of aspirin
in women with a history of PE in more than one
pregnancy or a history of PE that resulted in delivery
before 34 weeks’ gestation15. However, this subgroup
constitutes only approximately 0.3% of all pregnancies
and includes only 5% of women who develop preterm
PE14. Our approach to screening with the use of Bayes’
theorem to combine the a-priori risk from maternal factors
with biophysical and biochemical measurements obtained
at 11–13 weeks’ gestation is by far superior to those of
NICE and ACOG in identifying the group who would
benefit from prophylactic use of aspirin.
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Ensayo ASPRE: el comportamiento del cribado de preeclampsia pret e´rmino
RESUMEN
Objetivo Estudiar el comportamiento del cribado de pre-eclampsia prete´rmino y a te´rmino (PE) en la poblacio´n de
estudio que participa en el ensayo ASPRE (Cribado combinado basado en evidencia mediante mu´ltiples marcadores y
tratamiento aleatorizado de la paciente con aspirina para la prevencio´n de preeclampsia).
Me´todos Se trata de un estudio multice´ntrico prospectivo de primer trimestre sobre el cribado de PE prete´rmino en
26 941 embarazos con feto u´nico, mediante un algoritmo que combina factores maternos como la presio´n arterial
promedio, el ı´ndice de pulsatilidad de la arteria uterina y la proteı´na plasma´tica A del suero materno asociada al
embarazo y el factor de crecimiento de la placenta a las 11-13 semanas de gestacio´n. Se invito´ a las mujeres con
posibilidades de ser elegidas por tener un riesgo estimado de PE prete´rmino >1 entre 100 a participar en un ensayo
doble ciego de aspirina (150 mg por dı´a) versus un placebo, desde las semanas 11-14 a las 36 semanas de gestacio´n, que
resulto´ en una reduccio´n de la incidencia de PE prematura de un 62% en el grupo que tomo´ aspirina. En la poblacio´n
en la que se hizo el cribado, despue´s del ajuste del efecto de la aspirina en las mujeres que recibieron este tratamiento, se
estimaron las tasas de deteccio´n (TD) y las tasas de falsos positivos (TFP) para el parto con PE <37 y >37 semanas. Se
excluyeron 1144 (4,2%) embarazos debido a falta de seguimiento o abandono del estudio (n = 716), aborto (n = 243)
o terminacio´n (n = 185).
Resultados La poblacio´n estudiada de 25 797 embarazos incluyo´ 180 (0,7%) casos de PE prete´rmino, 450 (1,7%) de
PE a te´rmino y 25 167 (97,6%) sin PE. En el cribado combinado del primer trimestre para PE prete´rmino con un lı´mite
de riesgo de 1 entre 100, la TD fue del 76,7% (138/180) para PE prete´rmino y 43,1% (194/450) para PE a te´rmino,
con una tasa positiva del cribado del 10,5% (2707/25797) y una TFP del 9,2% (2375/25797).
Conclusio´n El comportamiento del cribado en el estudio ASPRE fue comparable con el de un estudio
de aproximadamente 60 000 embarazos con feto u´nico utilizados para el desarrollo del algoritmo; en ese estudio,
el cribado combinado detecto´ el 76,6% de los casos de PE prete´rmino y el 38,3% de los de PE a te´rmino con una TFP
del 10%.
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